Melanoma-inhibiting activity (MIA) mRNA is not exclusively transcribed in melanoma cells: Low levels of MIA mRNA are present in various cell types and in peripheral blood

British Journal of Cancer

Volumn 81, Issue 6, 1999, Pages 1066-1070

  De Vries, T J ^a,b   Fourkour, A ^a   Punt, C J A ^a   Diepstra, H ^a   Ruiter, D J ^a   Van Muijen, G N P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Circulating cancer cells; Melanoma; MIA; RT PCR

Indexed keywords

MELANOMA INHIBITORY ACTIVITY; MESSENGER RNA; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CANCER CELL CULTURE; CANCER DIAGNOSIS; CELL TYPE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; HUMAN; HUMAN CELL; MARKER GENE; MELANOMA CELL; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RNA ANALYSIS; RNA TRANSCRIPTION; VOLUNTEER;

AMINO ACID SEQUENCE; EXTRACELLULAR MATRIX PROTEINS; FALSE NEGATIVE REACTIONS; HUMANS; MELANOMA; MOLECULAR SEQUENCE DATA; MONOPHENOL MONOOXYGENASE; NEOPLASM PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0032726225     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690808     Document Type: Article

References (21)

1. Blesch A, Bosserhoff A-K, Apfel R, Behl C, Hessdoerfer B, Schmitt A, Jachimczak P, Lottspeich F, Buettner R and Bogdahn U (1994) Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res 54: 5695-5701
2. Bosserhoff A-K, Hein R, Bogdahn U and Buettner R (1996) Structure and promoter analysis of the gene encoding the human melanoma-inhibiting protein MIA. J Biol Chem 271: 490-495
3. Bosserhoff A-K, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R, Stolz W and Bucttner R (1997) Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 57: 3149-3153
4. Brossart P, Keilholz U, Willhauck M, Scheibenbogen C, Mohler T and Hunstein W (1993) Hematogenous spread of malignant melanoma cells in different stages of disease. J Invest Dermatol 101: 887-889
5. Brossart P, Schmier IW, Kruger S, Willhauck M, Scheibenbogen C, Mohler T and Keilholz U (1995) A polymerase chain reaction based semiquantative assessment of malignant melanoma cells in peripheral blood. Cancer Res 55: 4065-4068
6. Brouwenstijn N, Slager EH, Bakker ABH, Schreurs MWJ, Van der Spek CW, Adema GJ, Schrier PI and Figdor CG (1997) Transcription of the gene encoding melanoma-associated antigen gp100 in tissue and cell lines other than those of the melanocytic lineage. Br J Cancer 76: 1562-1566
7. Burchill SA, Bradbury FM, Pittman K, Southgate J, Smith B and Selby P (1995) Detection of epithelial cancer cells in peripheral blood by reverse transcription-polymerase chain reaction. Br J Cancer 71: 278-281
8. Chelly J, Concordet J, Kaplan J and Kahn A (1989) Illegilimate transcription: transcription of any gene in any cell type. Proc Natl Acad Sci USA 86: 2617-2621
9. Curry BJ, Myers K and Hersey P (1998) Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment, and recurrence from melanoma. J Clin Oncol 16: 1760-1769
10. De Vries TJ, Fourkour A, Wobbes T, Verkroost G, Ruiter DJ and Van Muijen GNP (1997) Heterogeneous expression of immunotherapy candidate proteins gp100. MART-1 and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res 57: 3223-3229
11. De Vries TJ, Fourkour A, Punt CJA, Van de Locht LT, Wobbes T, Van den Bosch S, De Rooij MJM, Mensink EJ, Ruiter DJ and Van Muijen GNP (1999) Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative PCR. Br J Cancer 80: 883-891
12. Hoon DS, Wang Y, Dale PS, Conrad AJ. Schmid P, Garrison D, Kuo C, Foshag LJ, Nizze AJ and Morton DL (1995) Detection of occult melanoma cells in the blood with a multiple marker polymerase chain reaction assay. J Clin Oncol 13: 2109-2116
13. Keilholz U (1996) Diagnostic PCR in melanoma: methods and quality assurance. Eur J Cancer 32: 1661-1663
14. Keiholz U, Willhauck M, Scheibenbogen C, De Vries TJ and Burchill S (1997) Polymerase chain reaction detection of circulating tumour cells. Melanoma Res 7: S133-S141
15. Kunter U, Buer J, Probst M, Duensing S, Dallmann I, Grosse J, Kirchner H, Schluepen EM, Volkenandt M, Ganser A and Atzpodien J (1996) Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst 88: 590-594
16. La Valle GJ, Williams NY, Walker MJ, Triozzi PL and Barbera Guillem E (1998) Expression of melanoma inhibitory activity in the peripheral blood of melanoma patients by the reverse transcription polymerase chain reaction (RT PCR). Proc Am Assoc Cancer Res 39: 229(Abstract)
17. Mellado B, Colomer D, Castel T, Munoz M, Carballo E, Galan M, Mascaro JM, Vives-Corrons JL, Grau JJ and Estape J (1996) Detection of circulating neoplastic cells by reverse transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis. J Clin Oncol 14: 2091-2097
18. Mori M, Mimori K, Tanaka F, Ueo H, Sugimachi K and Akiyoshi T (1997) Molecular diagnosis of circulating cancer cells using MAGE gene assays. JAMA 278: 476-477
19. Smith B, Selby P, Southgate J, Pittman K, Bradley C and Blair GE (1991) Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 338: 1227-1229
20. Van Groningen JJM, Bloemers HPJ and Swart GWM (1995) Identification of melanoma inhibitory activity and other differentially expressed messenger RNAs in human melanoma cell lines with different metastatic capacity by messenger RNA differential display. Cancer Res 55: 6237-6243
21. Wimmer M, Meyer JC, Seifert B, Dummer R, Flace A and Burg G (1997) Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy. Cancer Res 57: 5073-5076